Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels.
OBJECTIVE
The mechanisms by which apolipoprotein E (apoE) can promote the regression of atherosclerosis are not well understood. This study examined whether apoE can promote atherosclerosis regression independently of lowering plasma cholesterol levels.


RESULTS
We studied hypomorphic apoE mice (Apoe(h/h)), which express an apoE4-like form of mouse apoE at approximately 2% to 5% of normal levels in plasma and are normolipidemic. After 18 weeks of diet-induced hypercholesterolemia, which resulted in advanced aortic atherosclerotic lesions composed of a lipid-rich layer of foam cells covering a fibrotic core, 2 groups of mice were fed a chow diet for 16 weeks. One group continued to express low levels of apoE; the other was induced to express physiological levels of plasma apoE by Cre-mediated recombination of the hypomorphic Apoe allele. In both groups, plasma cholesterol levels fell rapidly to similar levels, and histological analysis at 16 weeks revealed elimination of the foam-cell layer. However, physiological levels of plasma apoE also enhanced the removal of neutral lipids from the fibrotic cores.


CONCLUSIONS
These findings demonstrate for the first time that apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Using Apoeh/hMx1-Cre mice we have begun to address apolipoprotein E-mediated mechanisms of atherosclerosis regression. We report the existence of a cholesterol-independent role of apolipoprotein E in atherosclerosis regression. This mechanism is critical for lipid removal from the fibrotic component of the plaque but not from the foam cell-rich layer beneath the endothelium.
Raffai
Robert L
RL
Division of Vascular Surgery, Pacific Vascular Research Laboratories, Department of Surgery, University of California, San Francisco, USA. raffair@surgery.ucsf.edu <raffair@surgery.ucsf.edu>
Loeb
Samuel M
SM
Weisgraber
Karl H
KH
D000483:Alleles; D000818:Animals; D001018:Aortic Diseases / Q000178:diet therapy / Q000209:etiology / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D001057:Apolipoproteins E / Q000235:genetics / Q000502:physiology*; D001161:Arteriosclerosis / Q000178:diet therapy / Q000209:etiology / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D002784:Cholesterol / Q000097:blood; D003094:Collagen / Q000032:analysis; D004036:Diet, Atherogenic; D004041:Dietary Fats / Q000633:toxicity; D005355:Fibrosis; D005487:Foam Cells / Q000473:pathology; D005786:Gene Expression Regulation; D006937:Hypercholesterolemia / Q000150:complications / Q000235:genetics; D019426:Integrases / Q000378:metabolism; D008074:Lipoproteins / Q000097:blood; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D023421:Models, Animal; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology
D001057:Apolipoproteins E; D004041:Dietary Fats; D008074:Lipoproteins; D011993:Recombinant Fusion Proteins; C502425:apolipoprotein E (Arg61), mouse; D003094:Collagen; D002784:Cholesterol; C045073:Cre recombinase; D019426:Integrases